Mizuho reissued their buy rating on shares of Mylan N.V. (NASDAQ:MYL) in a research note released on Tuesday, October 24th. The firm currently has a $37.00 target price on the stock.
Other research analysts have also recently issued reports about the stock. Citigroup Inc. upgraded shares of Mylan N.V. from a neutral rating to a buy rating and increased their price target for the company from $36.00 to $42.00 in a research report on Wednesday, August 16th. UBS AG reiterated a buy rating and set a $46.00 price target (down from $50.00) on shares of Mylan N.V. in a research report on Thursday, August 10th. BMO Capital Markets reiterated a buy rating and set a $45.00 price target on shares of Mylan N.V. in a research report on Friday, September 29th. ValuEngine raised Mylan N.V. from a hold rating to a buy rating in a research note on Monday, October 2nd. Finally, BTIG Research increased their price objective on Mylan N.V. from $42.00 to $45.00 and gave the company a buy rating in a research note on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and thirteen have issued a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $41.49.
Shares of Mylan N.V. (NASDAQ:MYL) opened at $38.16 on Tuesday. The company has a current ratio of 1.46, a quick ratio of 0.84 and a debt-to-equity ratio of 1.05. The firm has a market capitalization of $20,470.40, a PE ratio of 8.12, a PEG ratio of 2.09 and a beta of 1.38. Mylan N.V. has a 52-week low of $29.39 and a 52-week high of $45.87.
Mylan N.V. (NASDAQ:MYL) last posted its quarterly earnings data on Monday, November 6th. The company reported $1.10 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.20 by ($0.10). Mylan N.V. had a return on equity of 20.63% and a net margin of 7.28%. The company had revenue of $2.99 billion during the quarter, compared to the consensus estimate of $3.09 billion. During the same quarter last year, the company posted $1.38 earnings per share. The firm’s revenue for the quarter was down 2.3% on a year-over-year basis. sell-side analysts predict that Mylan N.V. will post 4.56 EPS for the current year.
WARNING: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.dispatchtribunal.com/2017/11/12/mizuho-reaffirms-buy-rating-for-mylan-n-v-myl.html.
Hedge funds have recently modified their holdings of the business. Canada Pension Plan Investment Board lifted its stake in shares of Mylan N.V. by 99.5% during the 3rd quarter. Canada Pension Plan Investment Board now owns 1,217,413 shares of the company’s stock worth $38,189,000 after purchasing an additional 607,094 shares during the last quarter. FMR LLC increased its holdings in shares of Mylan N.V. by 19.8% in the second quarter. FMR LLC now owns 813,267 shares of the company’s stock valued at $31,572,000 after purchasing an additional 134,258 shares during the period. Swiss National Bank increased its holdings in shares of Mylan N.V. by 3.1% in the second quarter. Swiss National Bank now owns 1,661,842 shares of the company’s stock valued at $64,513,000 after purchasing an additional 50,100 shares during the period. Vivaldi Asset Management LLC acquired a new position in shares of Mylan N.V. in the second quarter valued at about $5,098,000. Finally, Advisors Capital Management LLC increased its holdings in shares of Mylan N.V. by 4.7% in the second quarter. Advisors Capital Management LLC now owns 86,329 shares of the company’s stock valued at $3,351,000 after purchasing an additional 3,854 shares during the period. Institutional investors and hedge funds own 72.01% of the company’s stock.
About Mylan N.V.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.